The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / SLE Remission: The Treat-to-Target Approach

SLE Remission: The Treat-to-Target Approach

March 17, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Nonnakrit / SHUTTERSTOCK.COM

Nonnakrit / SHUTTERSTOCK.COM

SAN DIEGO—Treatment strategies for systemic lupus erythematosus (SLE) have changed a great deal over the years, but progress has been slow and inadequate. According to a 2011 survey, many patients with lupus still report that they have a low quality of life due to their health problems.1

You Might Also Like
  • Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
  • Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA
  • Clinical Remission Should Be Target of JIA Treatment: Task Force
Explore This Issue
March 2018
Also By This Author
  • RISE Lifts Research: The 2018 Annual Meeting Features 6 New Studies Based on RISE Data

Rheumatologists face the challenge to develop more successful therapeutic approaches and outcomes in these patients, said Ronald van Vollenhoven, MD, director of the Amsterdam Rheumatology and Immunology Center in The Netherlands. He shared the latest efforts by lupus researchers to shape a useful treat-to-target paradigm and definition of remission in SLE on Nov. 7 at the 2017 ACR/ARHP Annual Meeting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

New Biologic Option

Cyclophosphamide remains the pillar of treatment for severe lupus or lupus nephritis, but a low-dose protocol has now largely replaced the older, high-dose approach, he said.2 Belimumab, another lupus therapy approved in recent years, can be a safe, effective, steroid-sparing option for certain patients.3

Rheumatologists must still ask themselves if we are doing enough to improve the lives and long-term outcomes for lupus patients, he said. “Increasingly, we see that the most severe complications may be avoided for many of our patients. But something is still missing.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

According to the 2011 survey, which was conducted by a health economist in Sweden, lupus patients reported that they have a similar health-related quality of life as patients with late-stage chronic pulmonary obstructive disease (COPD) or cancer, said Dr. van Vollenhoven.

“This study reflects that some patients have a very poor quality of life. So our average result for treating lupus is still not very good. It is an expensive disease due to direct and indirect costs. How can we do better? One way is to develop better medications, and we always want that. But we can’t sit around and wait for that to happen.” Excitement reigns when new therapies emerge, but that enthusiasm can wane when treatments don’t prove as successful as we hoped, he said. “What we are trying to achieve is to use the existing therapies in a better way and to develop better strategies [for] how to use them.”

Refined Treatment Targets

Better outcomes may come from the development of a treat-to-target paradigm for SLE, he said. Treat-to-target approaches often follow this path: Identify a target for each patient to achieve, intervene with therapy, determine along with the patient when it is time to reassess the treatment plan, and then, if a target is not met, modify the intervention. The treat-to-target approach has been used in hypertension, a relatively simple condition to manage, and is widely used in the management of rheumatoid arthritis.4 Will it work in lupus, which is much more complex?

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports, SLE (Lupus) Tagged With: ACR/ARHP Annual Meeting, Lupus, Remission, SLEIssue: March 2018

You Might Also Like:
  • Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
  • Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA
  • Clinical Remission Should Be Target of JIA Treatment: Task Force
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.